Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Lenvatinib With Pembrolizumab in Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
NCT04393350Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Jun 2020
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in clear cell renal cell carcinoma (ccRCC), sponsored by Emory University. Started Jun 2020; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04393350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393350.